Last reviewed · How we verify
AGT4, AGZ
AGT4, AGZ is a angiotensin II receptor blocker Small molecule drug developed by Ahn-Gook Pharmaceuticals Co.,Ltd. It is currently in Phase 3 development for Hypertension, Heart failure.
AGT4 and AGZ are angiotensin II receptor blockers.
AGT4 and AGZ are being studied in combination as a treatment for Primary Hypercholesterolemia. This study, NCT05206578, is evaluating the efficacy and safety of combination therapy of AGT and AGZ compared to monotherapy of AGT in patients with Primary Hypercholesterolemia.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AGT4, AGZ |
|---|---|
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Drug class | angiotensin II receptor blocker |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
They work by blocking the action of angiotensin II at its receptor, leading to vasodilation and a decrease in blood pressure. This results in a reduction in the workload on the heart and a decrease in the risk of cardiovascular events.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Dizziness
- Headache
- Fatigue
- Cough
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGT4, AGZ CI brief — competitive landscape report
- AGT4, AGZ updates RSS · CI watch RSS
- Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI
Frequently asked questions about AGT4, AGZ
What is AGT4, AGZ?
How does AGT4, AGZ work?
What is AGT4, AGZ used for?
Who makes AGT4, AGZ?
What drug class is AGT4, AGZ in?
What development phase is AGT4, AGZ in?
What are the side effects of AGT4, AGZ?
What does AGT4, AGZ target?
Related
- Drug class: All angiotensin II receptor blocker drugs
- Target: All drugs targeting AT1 receptor
- Manufacturer: Ahn-Gook Pharmaceuticals Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing